

US Patent & Trademark Office

Patent Public Search | Text View

| | |
|----------------------|-------------------|
| United States Patent | 12390428 |
| Kind Code | B2 |
| Date of Patent | August 19, 2025 |
| Inventor(s) | Tabuteau; Herriot |

Bupropion and dextromethorphan for reduction of suicide risk in depression patients

Abstract

This disclosure relates to a method of treating depression and/or reducing risk of suicide, comprising administering a combination of about 90 mg to about 120 mg of bupropion hydrochloride, or a molar equivalent amount of another form of bupropion, and about 40 mg to about 50 mg of dextromethorphan hydrobromide, or a molar equivalent amount of another form of dextromethorphan. The combination may be administered twice a day to a human being suffering from major depressive disorder and having a score of 3 or greater on the Suicidality Item of the Montgomery-Åsberg Depression Rating Scale (MADRS-SI).

| | |
|-------------------|--|
| Inventors: | Tabuteau; Herriot (New York, NY) |
| Applicant: | ANTECIP BIOVENTURES II LLC (New York, NY) |
| Family ID: | 1000008762968 |
| Assignee: | ANTECIP BIOVENTURES II LLC (New York, NY) |
| Appl. No.: | 18/397220 |
| Filed: | December 27, 2023 |

Prior Publication Data

| | |
|----------------------------|-------------------------|
| Document Identifier | Publication Date |
| US 20240390297 A1 | Nov. 28, 2024 |

Related U.S. Application Data

continuation parent-doc US 18323714 20230525 US 11896563 child-doc US 18397220
continuation parent-doc WO PCT/US2021/061492 20211201 PENDING child-doc US 18323714
us-provisional-application US 63120160 20201201

Publication Classification

Int. Cl.: **A61K31/137** (20060101); **A61K31/485** (20060101); **A61P25/24** (20060101)

U.S. Cl.:

CPC **A61K31/137** (20130101); **A61K31/485** (20130101); **A61P25/24** (20180101);

Field of Classification Search

CPC: A61K (31/137); A61K (31/485); A61P (25/24)

References Cited

U.S. PATENT DOCUMENTS

| Patent No. | Issued Date | Patentee Name | U.S. Cl. | CPC |
|-------------------|--------------------|----------------------|-----------------|------------|
| 5358970 | 12/1993 | Ruff et al. | N/A | N/A |
| 5731000 | 12/1997 | Ruff et al. | N/A | N/A |
| 5763493 | 12/1997 | Ruff et al. | N/A | N/A |
| 6306436 | 12/2000 | Chungi et al. | N/A | N/A |
| 6780871 | 12/2003 | Glick et al. | N/A | N/A |
| 8088786 | 12/2011 | McKinney et al. | N/A | N/A |
| 8569328 | 12/2012 | Tabuteau | N/A | N/A |
| 9168234 | 12/2014 | Tabuteau | N/A | N/A |
| 9198905 | 12/2014 | Tabuteau | N/A | N/A |
| 9205083 | 12/2014 | Tabuteau | N/A | N/A |
| 9238032 | 12/2015 | Tabuteau | N/A | N/A |
| 9278095 | 12/2015 | Tabuteau | N/A | N/A |
| 9314462 | 12/2015 | Tabuteau | N/A | N/A |
| 9370513 | 12/2015 | Tabuteau | N/A | N/A |
| 9375429 | 12/2015 | Tabuteau | N/A | N/A |
| 9402843 | 12/2015 | Tabuteau | N/A | N/A |
| 9402844 | 12/2015 | Tabuteau | N/A | N/A |
| 9408815 | 12/2015 | Tabuteau | N/A | N/A |
| 9421176 | 12/2015 | Tabuteau | N/A | N/A |
| 9457023 | 12/2015 | Tabuteau | N/A | N/A |
| 9457025 | 12/2015 | Tabuteau | N/A | N/A |
| 9474731 | 12/2015 | Tabuteau | N/A | N/A |
| 9486450 | 12/2015 | Tabuteau | N/A | N/A |
| 9700528 | 12/2016 | Tabuteau | N/A | N/A |
| 9700553 | 12/2016 | Tabuteau | N/A | N/A |
| 9707191 | 12/2016 | Tabuteau | N/A | N/A |
| 9763932 | 12/2016 | Tabuteau | N/A | N/A |
| 9861595 | 12/2017 | Tabuteau | N/A | N/A |
| 9867819 | 12/2017 | Tabuteau | N/A | N/A |
| 9968568 | 12/2017 | Tabuteau | N/A | N/A |

| | | | | |
|----------|---------|----------|-----|-----|
| 10058518 | 12/2017 | Tabuteau | N/A | N/A |
| 10064857 | 12/2017 | Tabuteau | N/A | N/A |
| 10080727 | 12/2017 | Tabuteau | N/A | N/A |
| 10092560 | 12/2017 | Tabuteau | N/A | N/A |
| 10092561 | 12/2017 | Tabuteau | N/A | N/A |
| 10105327 | 12/2017 | Tabuteau | N/A | N/A |
| 10105361 | 12/2017 | Tabuteau | N/A | N/A |
| 10251879 | 12/2018 | Tabuteau | N/A | N/A |
| 10463634 | 12/2018 | Tabuteau | N/A | N/A |
| 10512643 | 12/2018 | Tabuteau | N/A | N/A |
| 10548857 | 12/2019 | Tabuteau | N/A | N/A |
| 10596167 | 12/2019 | Tabuteau | N/A | N/A |
| 10688066 | 12/2019 | Tabuteau | N/A | N/A |
| 10695304 | 12/2019 | Tabuteau | N/A | N/A |
| 10772850 | 12/2019 | Tabuteau | N/A | N/A |
| 10780064 | 12/2019 | Tabuteau | N/A | N/A |
| 10780066 | 12/2019 | Tabuteau | N/A | N/A |
| 10786469 | 12/2019 | Tabuteau | N/A | N/A |
| 10786496 | 12/2019 | Tabuteau | N/A | N/A |
| 10799497 | 12/2019 | Tabuteau | N/A | N/A |
| 10806710 | 12/2019 | Tabuteau | N/A | N/A |
| 10813924 | 12/2019 | Tabuteau | N/A | N/A |
| 10864209 | 12/2019 | Tabuteau | N/A | N/A |
| 10874663 | 12/2019 | Tabuteau | N/A | N/A |
| 10874664 | 12/2019 | Tabuteau | N/A | N/A |
| 10874665 | 12/2019 | Tabuteau | N/A | N/A |
| 10881624 | 12/2020 | Tabuteau | N/A | N/A |
| 10881657 | 12/2020 | Tabuteau | N/A | N/A |
| 10894046 | 12/2020 | Tabuteau | N/A | N/A |
| 10894047 | 12/2020 | Tabuteau | N/A | N/A |
| 10898453 | 12/2020 | Tabuteau | N/A | N/A |
| 10925842 | 12/2020 | Tabuteau | N/A | N/A |
| 10933034 | 12/2020 | Tabuteau | N/A | N/A |
| 10940124 | 12/2020 | Tabuteau | N/A | N/A |
| 10945973 | 12/2020 | Tabuteau | N/A | N/A |
| 10966941 | 12/2020 | Tabuteau | N/A | N/A |
| 10966942 | 12/2020 | Tabuteau | N/A | N/A |
| 10966974 | 12/2020 | Tabuteau | N/A | N/A |
| 10980800 | 12/2020 | Tabuteau | N/A | N/A |
| 11007189 | 12/2020 | Tabuteau | N/A | N/A |
| 11020389 | 12/2020 | Tabuteau | N/A | N/A |
| 11058648 | 12/2020 | Tabuteau | N/A | N/A |
| 11065248 | 12/2020 | Tabuteau | N/A | N/A |
| 11090300 | 12/2020 | Tabuteau | N/A | N/A |
| 11096937 | 12/2020 | Tabuteau | N/A | N/A |
| 11123343 | 12/2020 | Tabuteau | N/A | N/A |
| 11123344 | 12/2020 | Tabuteau | N/A | N/A |
| 11129826 | 12/2020 | Tabuteau | N/A | N/A |
| 11141388 | 12/2020 | Tabuteau | N/A | N/A |
| 11141416 | 12/2020 | Tabuteau | N/A | N/A |

| | | | | |
|----------|---------|----------|-----|-----|
| 11147808 | 12/2020 | Tabuteau | N/A | N/A |
| 11185515 | 12/2020 | Tabuteau | N/A | N/A |
| 11191739 | 12/2020 | Tabuteau | N/A | N/A |
| 11197839 | 12/2020 | Tabuteau | N/A | N/A |
| 11207281 | 12/2020 | Tabuteau | N/A | N/A |
| 11213521 | 12/2021 | Tabuteau | N/A | N/A |
| 11229640 | 12/2021 | Tabuteau | N/A | N/A |
| 11234946 | 12/2021 | Tabuteau | N/A | N/A |
| 11253491 | 12/2021 | Tabuteau | N/A | N/A |
| 11253492 | 12/2021 | Tabuteau | N/A | N/A |
| 11273133 | 12/2021 | Tabuteau | N/A | N/A |
| 11273134 | 12/2021 | Tabuteau | N/A | N/A |
| 11285118 | 12/2021 | Tabuteau | N/A | N/A |
| 11285146 | 12/2021 | Tabuteau | N/A | N/A |
| 11291638 | 12/2021 | Tabuteau | N/A | N/A |
| 11291665 | 12/2021 | Tabuteau | N/A | N/A |
| 11298351 | 12/2021 | Tabuteau | N/A | N/A |
| 11298352 | 12/2021 | Tabuteau | N/A | N/A |
| 11311534 | 12/2021 | Tabuteau | N/A | N/A |
| 11344544 | 12/2021 | Tabuteau | N/A | N/A |
| 11357744 | 12/2021 | Tabuteau | N/A | N/A |
| 11364233 | 12/2021 | Tabuteau | N/A | N/A |
| 11382874 | 12/2021 | Tabuteau | N/A | N/A |
| 11419867 | 12/2021 | Tabuteau | N/A | N/A |
| 11426370 | 12/2021 | Tabuteau | N/A | N/A |
| 11426401 | 12/2021 | Tabuteau | N/A | N/A |
| 11433067 | 12/2021 | Tabuteau | N/A | N/A |
| 11439636 | 12/2021 | Tabuteau | N/A | N/A |
| 11478468 | 12/2021 | Tabuteau | N/A | N/A |
| 11497721 | 12/2021 | Tabuteau | N/A | N/A |
| 11510918 | 12/2021 | Tabuteau | N/A | N/A |
| 11517542 | 12/2021 | Tabuteau | N/A | N/A |
| 11517543 | 12/2021 | Tabuteau | N/A | N/A |
| 11517544 | 12/2021 | Tabuteau | N/A | N/A |
| 11524007 | 12/2021 | Tabuteau | N/A | N/A |
| 11524008 | 12/2021 | Tabuteau | N/A | N/A |
| 11534414 | 12/2021 | Tabuteau | N/A | N/A |
| 11541021 | 12/2022 | Tabuteau | N/A | N/A |
| 11541048 | 12/2022 | Tabuteau | N/A | N/A |
| 11571399 | 12/2022 | Tabuteau | N/A | N/A |
| 11571417 | 12/2022 | Tabuteau | N/A | N/A |
| 11576877 | 12/2022 | Tabuteau | N/A | N/A |
| 11576909 | 12/2022 | Tabuteau | N/A | N/A |
| 11590124 | 12/2022 | Tabuteau | N/A | N/A |
| 11596627 | 12/2022 | Tabuteau | N/A | N/A |
| 11617728 | 12/2022 | Tabuteau | N/A | N/A |
| 11617747 | 12/2022 | Tabuteau | N/A | N/A |
| 11628149 | 12/2022 | Tabuteau | N/A | N/A |
| 11660273 | 12/2022 | Tabuteau | N/A | N/A |
| 11660274 | 12/2022 | Tabuteau | N/A | N/A |

| | | | | |
|--------------|---------|--------------------|-----|------------|
| 11717518 | 12/2022 | Tabuteau | N/A | N/A |
| 11730706 | 12/2022 | Tabuteau | N/A | N/A |
| 11752144 | 12/2022 | Tabuteau | N/A | N/A |
| 11779579 | 12/2022 | Tabuteau | N/A | N/A |
| 11839612 | 12/2022 | Tabuteau | N/A | N/A |
| 11844797 | 12/2022 | Tabuteau | N/A | N/A |
| 11883373 | 12/2023 | Tabuteau | N/A | N/A |
| 11896563 | 12/2023 | Tabuteau | N/A | A61P 25/24 |
| 11925636 | 12/2023 | Tabuteau | N/A | N/A |
| 11969421 | 12/2023 | Tabuteau | N/A | N/A |
| 11986444 | 12/2023 | Tabuteau | N/A | N/A |
| 12036191 | 12/2023 | Tabuteau | N/A | N/A |
| 12042473 | 12/2023 | Tabuteau | N/A | N/A |
| 12109178 | 12/2023 | Tabuteau | N/A | N/A |
| 12138260 | 12/2023 | Tabuteau | N/A | N/A |
| 12146889 | 12/2023 | Tabuteau | N/A | N/A |
| 12194005 | 12/2024 | Tabuteau | N/A | N/A |
| 12194006 | 12/2024 | Tabuteau | N/A | N/A |
| 12194036 | 12/2024 | Tabuteau | N/A | N/A |
| 2002/0035105 | 12/2001 | Caruso | N/A | N/A |
| 2003/0044462 | 12/2002 | Subramanian et al. | N/A | N/A |
| 2008/0044462 | 12/2007 | Trumbore et al. | N/A | N/A |
| 2010/0040679 | 12/2009 | Chang | N/A | N/A |
| 2010/0291225 | 12/2009 | Fanda et al. | N/A | N/A |
| 2015/0126541 | 12/2014 | Tabuteau | N/A | N/A |
| 2015/0126542 | 12/2014 | Tabuteau | N/A | N/A |
| 2015/0126543 | 12/2014 | Tabuteau | N/A | N/A |
| 2015/0126544 | 12/2014 | Tabuteau | N/A | N/A |
| 2015/0133485 | 12/2014 | Tabuteau | N/A | N/A |
| 2015/0133486 | 12/2014 | Tabuteau | N/A | N/A |
| 2015/0150830 | 12/2014 | Tabuteau | N/A | N/A |
| 2015/0157582 | 12/2014 | Tabuteau | N/A | N/A |
| 2015/0342947 | 12/2014 | Pollard et al. | N/A | N/A |
| 2016/0008352 | 12/2015 | Tabuteau | N/A | N/A |
| 2016/0030420 | 12/2015 | Tabuteau | N/A | N/A |
| 2016/0030421 | 12/2015 | Tabuteau | N/A | N/A |
| 2016/0128944 | 12/2015 | Chawrai et al. | N/A | N/A |
| 2016/0128998 | 12/2015 | Tabuteau | N/A | N/A |
| 2016/0136155 | 12/2015 | Tabuteau | N/A | N/A |
| 2016/0199321 | 12/2015 | Tabuteau | N/A | N/A |
| 2016/0228390 | 12/2015 | Tabuteau | N/A | N/A |
| 2016/0263099 | 12/2015 | Tabuteau | N/A | N/A |
| 2016/0263100 | 12/2015 | Tabuteau | N/A | N/A |
| 2016/0317475 | 12/2015 | Tabuteau | N/A | N/A |
| 2016/0317476 | 12/2015 | Tabuteau | N/A | N/A |
| 2016/0324807 | 12/2015 | Tabuteau | N/A | N/A |
| 2016/0339017 | 12/2015 | Tabuteau | N/A | N/A |
| 2016/0346276 | 12/2015 | Tabuteau | N/A | N/A |
| 2016/0361305 | 12/2015 | Tabuteau | N/A | N/A |
| 2016/0375008 | 12/2015 | Tabuteau | N/A | N/A |

| | | | | |
|--------------|---------|----------|-----|-----|
| 2016/0375012 | 12/2015 | Tabuteau | N/A | N/A |
| 2017/0007558 | 12/2016 | Tabuteau | N/A | N/A |
| 2017/0014357 | 12/2016 | Tabuteau | N/A | N/A |
| 2017/0252309 | 12/2016 | Tabuteau | N/A | N/A |
| 2017/0281617 | 12/2016 | Tabuteau | N/A | N/A |
| 2017/0304229 | 12/2016 | Tabuteau | N/A | N/A |
| 2017/0304230 | 12/2016 | Tabuteau | N/A | N/A |
| 2017/0304298 | 12/2016 | Tabuteau | N/A | N/A |
| 2017/0354619 | 12/2016 | Tabuteau | N/A | N/A |
| 2017/0360773 | 12/2016 | Tabuteau | N/A | N/A |
| 2017/0360774 | 12/2016 | Tabuteau | N/A | N/A |
| 2017/0360776 | 12/2016 | Tabuteau | N/A | N/A |
| 2018/0092906 | 12/2017 | Tabuteau | N/A | N/A |
| 2018/0116980 | 12/2017 | Tabuteau | N/A | N/A |
| 2018/0133195 | 12/2017 | Tabuteau | N/A | N/A |
| 2018/0207151 | 12/2017 | Tabuteau | N/A | N/A |
| 2018/0256518 | 12/2017 | Tabuteau | N/A | N/A |
| 2018/0360823 | 12/2017 | Tabuteau | N/A | N/A |
| 2019/0000835 | 12/2018 | Tabuteau | N/A | N/A |
| 2019/0008800 | 12/2018 | Tabuteau | N/A | N/A |
| 2019/0008801 | 12/2018 | Tabuteau | N/A | N/A |
| 2019/0008805 | 12/2018 | Tabuteau | N/A | N/A |
| 2019/0015407 | 12/2018 | Tabuteau | N/A | N/A |
| 2019/0083426 | 12/2018 | Tabuteau | N/A | N/A |
| 2019/0142768 | 12/2018 | Tabuteau | N/A | N/A |
| 2019/0192450 | 12/2018 | Tabuteau | N/A | N/A |
| 2019/0192507 | 12/2018 | Tabuteau | N/A | N/A |
| 2019/0216798 | 12/2018 | Tabuteau | N/A | N/A |
| 2019/0216800 | 12/2018 | Tabuteau | N/A | N/A |
| 2019/0216801 | 12/2018 | Tabuteau | N/A | N/A |
| 2019/0290601 | 12/2018 | Tabuteau | N/A | N/A |
| 2020/0022929 | 12/2019 | Tabuteau | N/A | N/A |
| 2020/0093762 | 12/2019 | Tabuteau | N/A | N/A |
| 2020/0147008 | 12/2019 | Tabuteau | N/A | N/A |
| 2020/0147075 | 12/2019 | Tabuteau | N/A | N/A |
| 2020/0206217 | 12/2019 | Tabuteau | N/A | N/A |
| 2020/0215055 | 12/2019 | Tabuteau | N/A | N/A |
| 2020/0215056 | 12/2019 | Tabuteau | N/A | N/A |
| 2020/0215057 | 12/2019 | Tabuteau | N/A | N/A |
| 2020/0215058 | 12/2019 | Tabuteau | N/A | N/A |
| 2020/0215059 | 12/2019 | Tabuteau | N/A | N/A |
| 2020/0222389 | 12/2019 | Tabuteau | N/A | N/A |
| 2020/0230078 | 12/2019 | Tabuteau | N/A | N/A |
| 2020/0230129 | 12/2019 | Tabuteau | N/A | N/A |
| 2020/0230130 | 12/2019 | Tabuteau | N/A | N/A |
| 2020/0230131 | 12/2019 | Tabuteau | N/A | N/A |
| 2020/0237751 | 12/2019 | Tabuteau | N/A | N/A |
| 2020/0237752 | 12/2019 | Tabuteau | N/A | N/A |
| 2020/0246280 | 12/2019 | Tabuteau | N/A | N/A |
| 2020/0261431 | 12/2019 | Tabuteau | N/A | N/A |

| | | | | |
|--------------|---------|----------|-----|-----|
| 2020/0297666 | 12/2019 | Tabuteau | N/A | N/A |
| 2020/0338022 | 12/2019 | Tabuteau | N/A | N/A |
| 2020/0360310 | 12/2019 | Tabuteau | N/A | N/A |
| 2020/0397723 | 12/2019 | Tabuteau | N/A | N/A |
| 2020/0397724 | 12/2019 | Tabuteau | N/A | N/A |
| 2020/0405664 | 12/2019 | Tabuteau | N/A | N/A |
| 2021/0000763 | 12/2020 | Tabuteau | N/A | N/A |
| 2021/0000764 | 12/2020 | Tabuteau | N/A | N/A |
| 2021/0000765 | 12/2020 | Tabuteau | N/A | N/A |
| 2021/0000768 | 12/2020 | Tabuteau | N/A | N/A |
| 2021/0000820 | 12/2020 | Tabuteau | N/A | N/A |
| 2021/0015768 | 12/2020 | Tabuteau | N/A | N/A |
| 2021/0015814 | 12/2020 | Tabuteau | N/A | N/A |
| 2021/0015815 | 12/2020 | Tabuteau | N/A | N/A |
| 2021/0023075 | 12/2020 | Tabuteau | N/A | N/A |
| 2021/0023076 | 12/2020 | Tabuteau | N/A | N/A |
| 2021/0030747 | 12/2020 | Tabuteau | N/A | N/A |
| 2021/0030749 | 12/2020 | Tabuteau | N/A | N/A |
| 2021/0030750 | 12/2020 | Tabuteau | N/A | N/A |
| 2021/0030751 | 12/2020 | Tabuteau | N/A | N/A |
| 2021/0046067 | 12/2020 | Tabuteau | N/A | N/A |
| 2021/0052521 | 12/2020 | Tabuteau | N/A | N/A |
| 2021/0060004 | 12/2020 | Tabuteau | N/A | N/A |
| 2021/0060005 | 12/2020 | Tabuteau | N/A | N/A |
| 2021/0069125 | 12/2020 | Tabuteau | N/A | N/A |
| 2021/0069128 | 12/2020 | Tabuteau | N/A | N/A |
| 2021/0077428 | 12/2020 | Tabuteau | N/A | N/A |
| 2021/0077429 | 12/2020 | Tabuteau | N/A | N/A |
| 2021/0077483 | 12/2020 | Tabuteau | N/A | N/A |
| 2021/0106546 | 12/2020 | Tabuteau | N/A | N/A |
| 2021/0177834 | 12/2020 | Tabuteau | N/A | N/A |
| 2021/0186899 | 12/2020 | Tabuteau | N/A | N/A |
| 2021/0186900 | 12/2020 | Tabuteau | N/A | N/A |
| 2021/0186901 | 12/2020 | Tabuteau | N/A | N/A |
| 2021/0186955 | 12/2020 | Tabuteau | N/A | N/A |
| 2021/0186956 | 12/2020 | Tabuteau | N/A | N/A |
| 2021/0196704 | 12/2020 | Tabuteau | N/A | N/A |
| 2021/0196705 | 12/2020 | Tabuteau | N/A | N/A |
| 2021/0205239 | 12/2020 | Tabuteau | N/A | N/A |
| 2021/0205240 | 12/2020 | Tabuteau | N/A | N/A |
| 2021/0205297 | 12/2020 | Tabuteau | N/A | N/A |
| 2021/0220293 | 12/2020 | Tabuteau | N/A | N/A |
| 2021/0220294 | 12/2020 | Tabuteau | N/A | N/A |
| 2021/0220348 | 12/2020 | Tabuteau | N/A | N/A |
| 2021/0260054 | 12/2020 | Tabuteau | N/A | N/A |
| 2021/0267967 | 12/2020 | Tabuteau | N/A | N/A |
| 2021/0338605 | 12/2020 | Tabuteau | N/A | N/A |
| 2021/0346370 | 12/2020 | Tabuteau | N/A | N/A |
| 2021/0361645 | 12/2020 | Tabuteau | N/A | N/A |
| 2021/0401828 | 12/2020 | Tabuteau | N/A | N/A |

| | | | | |
|--------------|---------|----------|-----|-----|
| 2021/0401829 | 12/2020 | Tabuteau | N/A | N/A |
| 2021/0401830 | 12/2020 | Tabuteau | N/A | N/A |
| 2021/0401831 | 12/2020 | Tabuteau | N/A | N/A |
| 2022/0008363 | 12/2021 | Tabuteau | N/A | N/A |
| 2022/0071930 | 12/2021 | Tabuteau | N/A | N/A |
| 2022/0071931 | 12/2021 | Tabuteau | N/A | N/A |
| 2022/0079892 | 12/2021 | Tabuteau | N/A | N/A |
| 2022/0096462 | 12/2021 | Tabuteau | N/A | N/A |
| 2022/0105086 | 12/2021 | Tabuteau | N/A | N/A |
| 2022/0133655 | 12/2021 | Tabuteau | N/A | N/A |
| 2022/0142950 | 12/2021 | Tabuteau | N/A | N/A |
| 2022/0193012 | 12/2021 | Tabuteau | N/A | N/A |
| 2022/0218631 | 12/2021 | Tabuteau | N/A | N/A |
| 2022/0218698 | 12/2021 | Tabuteau | N/A | N/A |
| 2022/0233470 | 12/2021 | Tabuteau | N/A | N/A |
| 2022/0233474 | 12/2021 | Tabuteau | N/A | N/A |
| 2022/0233518 | 12/2021 | Tabuteau | N/A | N/A |
| 2022/0233519 | 12/2021 | Tabuteau | N/A | N/A |
| 2022/0241220 | 12/2021 | Tabuteau | N/A | N/A |
| 2022/0241221 | 12/2021 | Tabuteau | N/A | N/A |
| 2022/0241269 | 12/2021 | Tabuteau | N/A | N/A |
| 2022/0241270 | 12/2021 | Tabuteau | N/A | N/A |
| 2022/0265639 | 12/2021 | Tabuteau | N/A | N/A |
| 2022/0280504 | 12/2021 | Tabuteau | N/A | N/A |
| 2022/0313689 | 12/2021 | Tabuteau | N/A | N/A |
| 2022/0323381 | 12/2021 | Tabuteau | N/A | N/A |
| 2022/0378779 | 12/2021 | Tabuteau | N/A | N/A |
| 2023/0045675 | 12/2022 | Tabuteau | N/A | N/A |
| 2023/0096437 | 12/2022 | Tabuteau | N/A | N/A |
| 2023/0099206 | 12/2022 | Tabuteau | N/A | N/A |
| 2023/0100008 | 12/2022 | Tabuteau | N/A | N/A |
| 2023/0100913 | 12/2022 | Tabuteau | N/A | N/A |
| 2023/0114111 | 12/2022 | Tabuteau | N/A | N/A |
| 2023/0131854 | 12/2022 | Tabuteau | N/A | N/A |
| 2023/0142244 | 12/2022 | Tabuteau | N/A | N/A |
| 2023/0210843 | 12/2022 | Tabuteau | N/A | N/A |
| 2023/0218550 | 12/2022 | Tabuteau | N/A | N/A |
| 2023/0225995 | 12/2022 | Tabuteau | N/A | N/A |
| 2023/0233491 | 12/2022 | Tabuteau | N/A | N/A |
| 2023/0241010 | 12/2022 | Tabuteau | N/A | N/A |
| 2023/0248668 | 12/2022 | Tabuteau | N/A | N/A |
| 2023/0248669 | 12/2022 | Tabuteau | N/A | N/A |
| 2023/0255905 | 12/2022 | Tabuteau | N/A | N/A |
| 2023/0263750 | 12/2022 | Tabuteau | N/A | N/A |
| 2023/0270740 | 12/2022 | Tabuteau | N/A | N/A |
| 2023/0277478 | 12/2022 | Tabuteau | N/A | N/A |
| 2023/0277479 | 12/2022 | Tabuteau | N/A | N/A |
| 2023/0277480 | 12/2022 | Tabuteau | N/A | N/A |
| 2023/0277481 | 12/2022 | Tabuteau | N/A | N/A |
| 2023/0293456 | 12/2022 | Tabuteau | N/A | N/A |

| | | | | |
|--------------|---------|----------|-----|-----|
| 2024/0000770 | 12/2023 | Tabuteau | N/A | N/A |
| 2024/0016797 | 12/2023 | Tabuteau | N/A | N/A |
| 2024/0024309 | 12/2023 | Tabuteau | N/A | N/A |
| 2024/0041862 | 12/2023 | Tabuteau | N/A | N/A |
| 2024/0041863 | 12/2023 | Tabuteau | N/A | N/A |
| 2024/0050383 | 12/2023 | Tabuteau | N/A | N/A |
| 2024/0066025 | 12/2023 | Tabuteau | N/A | N/A |
| 2024/0115524 | 12/2023 | Tabuteau | N/A | N/A |
| 2024/0148719 | 12/2023 | Tabuteau | N/A | N/A |
| 2024/0156751 | 12/2023 | Tabuteau | N/A | N/A |
| 2024/0165104 | 12/2023 | Tabuteau | N/A | N/A |
| 2024/0189302 | 12/2023 | Tabuteau | N/A | N/A |
| 2024/0197656 | 12/2023 | Tabuteau | N/A | N/A |
| 2024/0197720 | 12/2023 | Tabuteau | N/A | N/A |
| 2024/0238276 | 12/2023 | Tabuteau | N/A | N/A |
| 2024/0252451 | 12/2023 | Tabuteau | N/A | N/A |
| 2024/0269130 | 12/2023 | Tabuteau | N/A | N/A |
| 2024/0299319 | 12/2023 | Tabuteau | N/A | N/A |
| 2024/0299320 | 12/2023 | Tabuteau | N/A | N/A |
| 2024/0307408 | 12/2023 | Tabuteau | N/A | N/A |
| 2024/0390297 | 12/2023 | Tabuteau | N/A | N/A |
| 2024/0408040 | 12/2023 | Tabuteau | N/A | N/A |
| 2025/0009754 | 12/2024 | Tabuteau | N/A | N/A |
| 2025/0012821 | 12/2024 | Tabuteau | N/A | N/A |

FOREIGN PATENT DOCUMENTS

| Patent No. | Application Date | Country | CPC |
|--------------|------------------|---------|-----|
| 102016010170 | 12/2016 | BR | N/A |
| 4183391 | 12/2022 | EP | N/A |
| 101612197 | 12/2015 | KR | N/A |
| 1998050044 | 12/1997 | WO | N/A |
| 2003086362 | 12/2002 | WO | N/A |
| 2004089873 | 12/2003 | WO | N/A |
| 2009006194 | 12/2008 | WO | N/A |
| 2009050726 | 12/2008 | WO | N/A |
| 2015069809 | 12/2014 | WO | N/A |
| 2016125108 | 12/2015 | WO | N/A |
| 2020146412 | 12/2019 | WO | N/A |
| 2021202329 | 12/2020 | WO | N/A |
| 2021202419 | 12/2020 | WO | N/A |
| 2023004064 | 12/2022 | WO | N/A |

OTHER PUBLICATIONS

Spravato (esketamine), Highlights of Prescribing Information, revised Jul. 2020. cited by applicant
Nuedexta (dextromethorphan hydrobromide and quinidine sulfate), Highlights of Prescribing Information, revised Dec. 2022. cited by applicant
Aplenzin (bupropion hydrobromide), Highlights of Prescribing Information, revised Mar. 2022. cited by applicant
Tod et al., Quantitative Prediction of Cytochrome P450 (CYP) 2D6-Mediated Drug Interactions, Clinical Pharmacokinetics, 50(8), 519-530, Aug. 2011. cited by applicant

Kotlyar et al., Inhibition of CYP2D6 Activity by Bupropion, *Journal of Clinical Psychopharmacology*, 25(2), 226-229, Jun. 2005. cited by applicant

Pope et al., Pharmacokinetics of Dextromethorphan after Single or Multiple Dosing in Combination with Quinidine in Extensive and Poor Metabolizers, *The Journal of Clinical Pharmacology*, 44(10), 1132-1142, Oct. 2004. cited by applicant

Auvelity (dextromethorphan hydrobromide and bupropion hydrochloride), Highlights of Prescribing Information and Medication Guide, issued Dec. 2022. cited by applicant

International Preliminary Report on Patentability, PCT/US2021/061492, mailed on Jun. 15, 2023. cited by applicant

International Search Report and Written Opinion, PCT/US2021/061492 received on Jun. 15, 2023. cited by applicant

International Search Report and Written Opinion, PCT/US2022/012768 received on Jul. 5, 2023. cited by applicant

International Search Report and Written Opinion, PCT/US2023/067062 mailed on Jul. 12, 2023. cited by applicant

Axsome Therapeutics Announces Topline Results of the Stride-1 Phase 3 Trial in Treatment Resistant Depression and Expert Call to Discuss Clinical Implications, Mar. 2020 (retrieved from internet on Jul. 19, 2023). <axsometherapeuticsinc.gcs-web.com/node/9176/pdf>. cited by applicant

Anderson, A.; et al. "Efficacy and Safety of AXS-05, an Oral NMDA Receptor Antagonist with Multimodal Activity, in Major Depressive Disorder: Results of a Phase 2, Double-Blind, Active-Controlled Trial" ASCP Annual Meeting 2019 (retrieved from internet on Jul. 19, 2023). <d3dyybxyjb4kyh.cloudfront.net/pdfs/SOBP+2021+AXS-05+MDD+Poster+FINAL.pdf> (May 2019). cited by applicant

O'Gorman, C; et al. "Rapid Effects of AXS 05, an Oral NMDA Receptor Antagonist, in Major Depressive Disorder: Results from Two Randomized, Double Blind, Controlled Trials" ASCP Annual Meeting 2021 (retrieved from internet on Jul. 19, 2023). <d3dyybxyjb4kyh.cloudfront.net/pdfs/SOBP+2021+AXS-05+MDD+Poster+FINAL.pdf> (Jun. 2021). cited by applicant

O'Gorman, C.; et al. "PMH40 Effects of AXS-05 on Patient Reported Depressive Symptoms in Major Depressive Disorder: Results from the Gemini Trial" <doi.org/10.1016/j.jval.2021.04.662> (retrieved from internet on Jul. 19, 2023). *Value in Health*, Jun. 2021, vol. 24, Supplement 1, pp. S135. cited by applicant

O'Gorman, C.; et al. "P246. Rapid Antidepressant Effects and MADRS Core Symptom Improvements With AXS-05, an Oral NMDA Receptor Antagonist, in Major Depressive Disorder: Results From Two Randomized, Double-Blind, Controlled Trials" ACNP 60th Annual Meeting: Poster Abstracts P246 <nature.com/articles/s41386-021-01236-7> (retrieved from internet on Jul. 19, 2023). *Neuropsychopharmacol.* 46 (Suppl 1), 72-217, Dec. 2021. cited by applicant

International Preliminary Report on Patentability, PCT/US2022/012768, mailed on Jul. 27, 2023. cited by applicant

Nofziger et al., Evaluation of dextromethorphan with select antidepressant therapy for the treatment of depression in the acute care psychiatric setting, *Mental Health Clinician*, 9(2), 76-81, Mar. 2019. cited by applicant

Update: Bupropion Hydrochloride Extended-Release 300 mg Bioequivalence Studies, FDA, retrieved Mar. 2021. cited by applicant

FDA Draft Guidance on Bupropion Hydrochloride, revised Mar. 2013. cited by applicant

Forfivo XL (bupropion hydrochloride) extended-release tablets, for oral use, Highlights of Prescribing Information, revised Dec. 2019. cited by applicant

Forfivo XL (Bupropion HCl) extended-release tablet, NDA 22497, Jan. 25, 2010. cited by applicant

Wellbutrin XL (bupropion hydrochloride extended-release), Highlights of Prescribing Information, revised Mar. 2022. cited by applicant

Baker T. E. et al., Human Milk and Plasma Pharmacokinetics of Single-Dose Rimegepant 75mg in Healthy Lactating Women, *Breastfeeding Medicine*, 17(3), 277-282, 2022. cited by applicant

Berle J. O. et al., Antidepressant Use During Breastfeeding, *Current Women's Health Reviews*, 7(1), 28-34, Feb. 2011. cited by applicant

Briggs G. G. et al., Excretion of bupropion in breast milk, *Annals of Pharmacotherapy*, 27(4):431-433, Apr. 1993. cited by applicant

Chad L. et al., Update on antidepressant use during breastfeeding, *Canadian Family Physician*, 59(6), 633-634, Jun. 2013. cited by applicant

Chaudron L. H. et al., Bupropion and Breastfeeding: A case of a possible Infant Seizure, *The Journal of clinical psychiatry*, 65(6), 881-882, Jun. 2004. cited by applicant

Davis M. F. et al., Bupropion Levels in Breast Milk for 4 Mother-Infant Pairs: More Answers to Lingering Questions, *J. Clin. Psychiatry*, 70(2), 297-298, Feb. 2009. cited by applicant

Di Scalea T. L. et al., Antidepressant Medication Use during Breastfeeding, *Clinical obstetrics and gynecology*, 52 (3): 483-497, Sep. 2009. cited by applicant

Dwoskin L. P. et al., Review of the Pharmacology and Clinical Profile of Bupropion, and Antidepressant and Tobacco Use Cessation Agent, *CNS Drug Reviews*, 12(3-4), 178-207, Sep. 2006. cited by applicant

Gentile S, The safety of newer antidepressants in pregnancy and breastfeeding, *Drug Safety*, 28(2), 137-152, Feb. 2005. [doi: 10.2165/00002018-200528020-00005. PMID: 15691224.]. cited by applicant

Haas J. S. et al., Bupropion in breast milk: an exposure assessment for potential treatment to prevent post-partum tobacco use, *Tobacco Control*, 13(1), 52-56, Mar. 2004. cited by applicant

Ram D. et al., Antidepressants, anxiolytics, and hypnotics in pregnancy and lactation, *Indian J Psychiatry*, 57(Suppl 2): S354-S371, Jul. 2015. [doi:10.4103/0019-5545.161504]. cited by applicant

Weissman A. M. et al., Pooled Analysis of Antidepressant Levels in Lactating Mothers, Breast Milk, and Nursing Infants, *Am J Psychiatry*, 161(6), 1066-1078, Jun. 2004. cited by applicant

Horn J. R. et al., Get to Know an Enzyme: CYP2D6, *Pharmacy Times*, Jul. 2008, retrieved on Aug. 28, 2023. cited by applicant

International Search Report and Written Opinion, PCT/US2023/069286 mailed on Aug. 22, 2023. cited by applicant

International Search Report and Written Opinion, PCT/US2023/069239 mailed on Aug. 28, 2023. cited by applicant

International Search Report and Written Opinion, PCT/US2023/069367 mailed on Aug. 28, 2023. cited by applicant

International Search Report and Written Opinion, PCT/US2023/069655 mailed on Sep. 15, 2023. cited by applicant

International Search Report and Written Opinion, PCT/US2023/069371 mailed on Sep. 26, 2023. cited by applicant

International Search Report and Written Opinion, PCT/US2022/037913 mailed on Sep. 21, 2022. cited by applicant

International Search Report and Written Opinion, PCT/US2022/074713 mailed on Sep. 21, 2022. cited by applicant

International Preliminary Report on Patentability, PCT/US2022/037913, issued on Jan. 18, 2024. cited by applicant

International Preliminary Report on Patentability, PCT/US2022/074713, issued on Feb. 22, 2024. cited by applicant

Chinese Pat. No. 202080004041.1 Invalidation Notice and Request issued on Jan. 15, 2024.

(English translation included). cited by applicant
Ward K. and Citrome L.: "AXS-05: an investigational treatment for Alzheimer's disease-associated agitation", Expert Opinion on Investigational Drugs, Jul. 6, 2022, vol. 31, issue 8, pp. 773-780, DOI: 10.1080/13543784.2022.2096006. cited by applicant
Defendant Teva Pharmaceuticals, Inc.'s Invalidity Contentions for U.S. Pat. Nos. 11,752,144, 11,717,518, 11,730,706 and Exhibits A-C dated Apr. 11, 2024. cited by applicant
Goodnick, Psychotropic drugs and the ECG: focus on the QTc interval, Expert Opinion on Pharmacotherapy, vol. 3, No. 5, p. 479-498, 2002. cited by applicant
International Search Report and Written Opinion, PCT/US2024/046359 mailed on Nov. 28, 2024. cited by applicant
Tabuteau H, et al. "Effect of AXS-05 (Dextromethorphan-Bupropion) in Major Depressive Disorder: A Randomized Double-Blind Controlled Trial" Am J Psychiatry (2022) vol. 179 pp. 490-499. doi: 10.1176/appi.ajp.21080800. cited by applicant
International Preliminary Report on Patentability, PCT/US2023/067062, mailed on Nov. 28, 2024. cited by applicant
International Search Report and Written Opinion, PCT/US2024/043903 mailed on Nov. 28, 2024. cited by applicant
International Preliminary Report on Patentability, PCT/US2023/069286, mailed on Jan. 9, 2025. cited by applicant
International Preliminary Report on Patentability, PCT/US2023/069371, mailed on Jan. 9, 2025. cited by applicant
International Preliminary Report on Patentability, PCT/US2023/069655, mailed on Jan. 16, 2025. cited by applicant

Primary Examiner: Weddington; Kevin E

Attorney, Agent or Firm: PROCOPIO, CORY, HARGREAVES & SAVITCH LLP

Background/Summary

CROSS-REFERENCE TO RELATED APPLICATIONS (1) This application is a continuation of U.S. patent application Ser. No. 18/323,714, filed May 25, 2023; which is a continuation of International Pat. App. No. PCT/US2021/061492, filed Dec. 1, 2021; which claims the benefit of U.S. Provisional App. Nos. 63/120,160, filed Dec. 1, 2020, 63/120,672, filed Dec. 2, 2020, and 63/122,902, filed Dec. 8, 2020; all of which are incorporated by reference herein in their entireties.

SUMMARY

(1) This disclosure relates to a method of treating depression and/or reducing risk of suicide, comprising administering combination of about 90 mg to about 120 mg of bupropion hydrochloride, or a molar equivalent amount of another form of bupropion, and about 40 mg to about 50 mg of dextromethorphan hydrobromide, or a molar equivalent amount of another form of dextromethorphan. The combination may be administered twice a day to a human being suffering from major depressive disorder and having a score of 3 or greater on the Suicidality Item of the Montgomery-Åsberg Depression Rating Scale (MADRS-SI).

Description

DETAILED DESCRIPTION

(1) The combination of dextromethorphan and bupropion may be used to treat depression, such as major depressive disorder and/or reduce the risk of suicide. Patients being treated by this combination may suffer from depression and may have a score of 2 or greater, or 3 or greater on the Suicidality Item of the Montgomery-Åsberg Depression Rating Scale (MADRS-SI).

(2) Dextromethorphan is rapidly metabolized in the human liver. This rapid hepatic metabolism may limit systemic drug exposure in individuals who are extensive metabolizers. Human beings can be: 1) extensive metabolizers of dextromethorphan—those who rapidly metabolize dextromethorphan; 2) poor metabolizers of dextromethorphan—those who only poorly metabolize dextromethorphan; or 3) intermediate metabolizers of dextromethorphan—those whose metabolism of dextromethorphan is somewhere between that of an extensive metabolizer and a poor metabolizer. Extensive metabolizers can also be ultra-rapid metabolizers. Non-poor metabolizers of dextromethorphan include extensive metabolizers of dextromethorphan and intermediate metabolizers of dextromethorphan. Extensive metabolizers of dextromethorphan are a significant portion of the human population. Dextromethorphan can, for example, be metabolized to dextrorphan.

(3) When given the same oral dose of dextromethorphan, plasma levels of dextromethorphan are significantly higher in poor metabolizers or intermediate metabolizers as compared to extensive metabolizers of dextromethorphan. The low plasma concentrations of dextromethorphan can limit its clinical utility as a single agent for extensive metabolizers, and possibly intermediate metabolizers, of dextromethorphan. Bupropion inhibits the metabolism of dextromethorphan, and raises the plasma concentration of dextromethorphan, and can thus improve its therapeutic efficacy. Similarly, bupropion may allow dextromethorphan to be given less often or in a lower amount, such as once a day instead of twice a day, once a day instead of three times a day, once a day instead of four times a day, twice a day instead of three times a day, or twice a day instead of four times a day, without loss of therapeutic efficacy.

(4) The MADRS is a clinician-rated scale. The MADRS is used to assess depressive symptomatology during the previous week. Subjects are rated on 10 items to assess symptoms: 1) apparent sadness, 2) reported sadness, 3) inner tension, 4) reduced sleep, 5) reduced appetite, 6) concentration difficulties, 7) lassitude, 8) inability to feel, 9) pessimistic thoughts, 10) suicidal thoughts. Each item yields a score of 0 to 6.

(5) The overall score ranges from 0 to 60. A score of 0 indicates the absence of symptoms, and a score of 60 indicates symptoms of maximum severity. A total score ranging from 0 to 6 indicates that the patient is in the normal range (no depression), a score ranging from 7 to 19 indicates “mild depression,” 20 to 34 indicates “moderate depression,” a score of 35 and greater indicates “severe depression.”

(6) In some embodiments, the human being that is treated with a combination of dextromethorphan and bupropion, e.g. for a type of depression, has, or is selected for having, a MADRS score that is at least about 20, at least about 25, at least about 30, at least about 35, at least about 40, at least about 45, at least about 50, at least about 55, about 20-25, about 25-30, about 30-35, about 35-40, about 40-45, about 45-50, about 50-55, about 55-60, about 25-35, about 35-45, about 45-60, about 25-40, or about 40-60.

(7) In some embodiments, treatment with the combination of dextromethorphan and bupropion results in the human being having a MADRS score that is reduced by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, about 10-20%, about 20-30%, about 30-40%, about 40-50%, about 50-60%, about 60-80%, about 80-90%, or about 90-100% as compared to baseline or placebo. In some embodiments, the reduction is compared to baseline. In some embodiments, the reduction is compared to placebo. In some embodiments, the reduction is compared to the baseline before treatment.

(8) In some embodiments, treatment with the combination of dextromethorphan and bupropion results in the human being having a MADRS score that is less than 34, about 20-34, about 7-19, about 0-6, about 30 or less, about 26 or less, about 25 or less, about 20 or less, about 19 or less, about 17 or less, about 14 or less, about 12 or less, about 10 or less, about 8 or less, about 6 or less, about 5 or less, about 4 or less, about 3 or less, about 2 or less, about 1 or less, about 0, about 7 or less, about 0-6, about 1-2, about 2-3, about 3-4, about 4-5, about 5-6, about 6-7, about 7-8, about 8-9, about 9-10, about 10-11, about 11-12, about 12-13, about 13-14, about 14-15, about 15-16, about 16-17, about 17-18, about 18-19, about 19-20, about 18-20, about 1-3, about 3-6, about 6-9, about 9-12, about 12-14, about 12-15, about 15-19, or about 15-20.

(9) Depression may be manifested by depressive symptoms. These symptoms may include psychological changes such as changes in mood, feelings of intense sadness, despair, mental slowing, loss of concentration, pessimistic worry, agitation, anxiety, irritability, guilt, anger, feelings of worthlessness, reckless behavior, suicidal thoughts or attempts, and/or self-deprecation. Physical symptoms of depression may include insomnia, anorexia, appetite loss, weight loss, weight gain, decreased energy and libido, fatigue, restlessness, aches, pains, headaches, cramps, digestive issues, and/or abnormal hormonal circadian rhythms.

(10) Some patients, even after treatment with medications such as antidepressants, may have an inadequate or no response to the treatment. Treatment resistant depression (TRD), or treatment-refractory depression, is a condition generally associated with patients who have failed treatment with at least two antidepressants. Part of the diagnosis for TRD is for the patient to have had an inadequate response to treatment with the antidepressants after an adequate dose and adequate course, e.g. in the current depressive episode. TRD may be more difficult to treat due to the comorbidity of other medical or psychological illnesses, such as drug/alcohol abuse or eating disorders, or TRD being misdiagnosed. Some TRD patients have had an inadequate response to 1, 2, 3, or more adequate antidepressant treatment trials or have failed or had an inadequate response to 1, 2, 3, or more prior antidepressant treatments. In some embodiments, a patient being treated for treatment resistant depression has failed treatment with at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more antidepressant therapies. In addition to other depressed patients, the combination of bupropion and dextromethorphan may be effective in treating patients suffering from treatment resistant depression with suicidal ideation.

(11) Patients who may benefit from the treatments described herein include pediatric patients, such as patients under about 18 years of age, about 0-5 years of age, about 5-10 years of age, about 10-12 years of age, or about 12-18 years of age; adult patients, such as patients having an age of about 18-70 years, about 18-65 years, about 18-30 years, about 18-20 years, about 20-30 years, about 30-40 years, about 40-50 years, about 50-60 years, about 60-70 years, about 70-80 years, about 80-90 years, about 30-50 years, about 50-65 years; elderly patients, such as patients over 65 years of age, about 65-75 years of age, about 75-90 years of age, or over 90 years of age; and about 41 years of age or older.

(12) In some embodiments, the human being that is treated with a combination of dextromethorphan and bupropion, e.g. for a type of depression, is, or is selected for being, of Asian descent. In some embodiments, the human being that is treated with a combination of dextromethorphan and bupropion, e.g. for a type of depression, is, or is selected for being, of Japanese descent. In some embodiments, the human being that is treated with a combination of dextromethorphan and bupropion, e.g. for a type of depression, is, or is selected for being, of Korean descent. In some embodiments, the human being that is treated with a combination of dextromethorphan and bupropion, e.g. for a type of depression, is, or is selected for being, of Chinese descent. The assignment of an individual as having Asian, Chinese, Japanese, or Korean descent may be based upon self-reporting by the individual. In these Asian individuals, the combination of dextromethorphan and bupropion may be effective for treating depression where bupropion alone is not effective for treating depression. This may be of particular importance

because patients of Asian descent may suffer from more severe depression than those of other ethnic or cultural groups.

(13) In some embodiments, the human being that is treated with a combination of dextromethorphan and bupropion, e.g. for a type of depression, is suffering from, or is selected for suffering from, a major depressive episode that has lasted between about 8 weeks and about 24 months, about 1-6 months, about 6-12 months, about 1-2 years, at least about 1 week, at least about 2 weeks, at least about 3 weeks, at least about 4 weeks, at least about 6 weeks, at least 7 weeks, at least about 2 months, at least about 3 months, at least about 4 months, at least about 5 months, at least about 6 months, at least about 9 months, at least about 1 year, at least about 18 months, at least about 2 years, about 1-12 weeks, about 3-6 months, about 6-9 months, about 9-12 months, about 12-18 months, about 18-24 months, about 2-4 years, about 4-6 years, about 6-10 years, about 10-20 years or longer.

(14) In some embodiments, the human being that is treated with a combination of dextromethorphan and bupropion, e.g. for a type of depression, has, or is selected having, about 1-100, or more, lifetime depressive episodes, such as a major depressive episodes, including at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 10, at least 15, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, 1-5, 5-10, 10-20, 20-30, 30-40, 40-50, 50-60, 60-70, 70-80, 80-90, 90-100, or 4-7 lifetime depressive episodes.

(15) In some embodiments, the human being that is treated with a combination of dextromethorphan and bupropion, e.g. for a type of depression, has, or is selected for having, an inadequate response to one or more prior antidepressant therapies, e.g. 1, 2, 3, 4, 5 or more prior antidepressant therapies, including prior antidepressant therapies in the current depressive episode (e.g. the current major depressive episode).

(16) In some embodiments, the human being that is treated with a combination of dextromethorphan and bupropion, e.g. for a type of depression, is, or is selected for being male. In some embodiments, the human being that is treated with a combination of dextromethorphan and bupropion, e.g. for a type of depression, is, or is selected for being female.

(17) The combination of bupropion and dextromethorphan is administered once a day or twice a day for at least one week, at least two weeks, at least three weeks, at least four weeks, at least six weeks, at least eight weeks, at least three months, at least four months, at least five months, or at least six months; and/or may be administered for up to four months, up to six months, up to one year, up to two years, or longer. In some embodiments, the combination of bupropion and dextromethorphan is administered twice a day for at least one week, at least two weeks, at least three weeks, at least four weeks, at least six weeks, at least eight weeks, at least three months, at least four months, at least five months, or at least six months; and/or may be administered for up to four months, up to six months, up to one year, up to two years, or longer. In some embodiments, the combination of bupropion and dextromethorphan is administered once a day for 1, 2, 3, 4, 5, 6, or 7 days, and then administered twice a day thereafter.

(18) In some embodiments, at least about 50 mg, at least about 70 mg, at least about 90 mg, at least about 100 mg, at least about 110 mg, or at least about 120 mg of bupropion hydrochloride, or a molar equivalent amount of another form of bupropion (such as another salt form or the free base form) is administered once a day or twice a day. In some embodiments, the bupropion is administered once a day for 1, 2, 3, 4, 5, 6, or 7 days, and then administered twice a day thereafter.

(19) In some embodiments, up to about 70 mg, up to about 90 mg, up to about 100 mg, up to about 110 mg, up to about 120 mg up to about 130 mg, or up to about 150 mg, of bupropion hydrochloride, or a molar equivalent amount of another form of bupropion (such as another salt form or the free base form) is administered once a day or twice a day. In some embodiments, the bupropion is administered once a day for 1, 2, 3, 4, 5, 6, or 7 days, and then administered twice a day thereafter.

(20) In some embodiments, about $0.8 \times$ mg to about $1.2 \times$ mg of bupropion hydrochloride, or a molar equivalent amount of another form of bupropion (such as another salt form or the free base form) is administered once or twice a day, wherein x is about 50 mg (e.g. 40-60 mg), about 60 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg, about 120 mg, or about 140 mg. In some embodiments, the bupropion is administered once a day for 1, 2, 3, 4, 5, 6, or 7 days, and then administered twice a day thereafter.

(21) In some embodiments, about 50-150 mg, about 90-120 mg, about 100-110 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of another form of bupropion (such as another salt form or the free base form) is administered once a day or twice a day. In some embodiments, the bupropion is administered once a day for 1, 2, 3, 4, 5, 6, or 7 days, and then administered twice a day thereafter.

(22) In some embodiments, at least about 30 mg, at least about 35 mg, at least about 40 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of another form of dextromethorphan (such as another salt form or the free base form) is administered once a day or twice a day. In some embodiments, the dextromethorphan is administered once a day for 1, 2, 3, 4, 5, 6, or 7 days, and then administered twice a day thereafter.

(23) In some embodiments, up to about 50 mg, up to about 55 mg, up to about 60 mg, or up to about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of another form of dextromethorphan (such as another salt form or the free base form) is administered once a day or twice a day. In some embodiments, the dextromethorphan is administered once a day for 1, 2, 3, 4, 5, 6, or 7 days, and then administered twice a day thereafter.

(24) In some embodiments, about $0.8 \times$ mg to about $1.2 \times$ mg of dextromethorphan hydrobromide, or a molar equivalent amount of another form of dextromethorphan (such as another salt form or the free base form) is administered once a day or twice a day, wherein x is about 30 mg (e.g. 24-36 mg), about 40 mg, about 50 mg, or about 60 mg. In some embodiments, the dextromethorphan is administered once a day for 1, 2, 3, 4, 5, 6, or 7 days, and then administered twice a day thereafter.

(25) In some embodiments, about 30-60 mg, about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of another form of dextromethorphan (such as another salt form or the free base form) is administered once a day or twice a day. In some embodiments, the dextromethorphan is administered once a day for 1, 2, 3, 4, 5, 6, or 7 days, and then administered twice a day thereafter.

(26) Administration of the combination of bupropion and dextromethorphan may improve depression symptoms, such as the Montgomery-Åsberg Depression Rating Scale (MADRS) score. It may also reduce the Suicidality Item of the MADRS (MADRS-SI), such as by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 80%, or up to about 100%, e.g. after the combination is administered daily, such as twice a day, for one week, two weeks, four weeks, six weeks, eight weeks, or twelve weeks, etc.

(27) In some embodiments, after eight days of receiving the combination of bupropion and dextromethorphan twice a day, the C.sub.max of dextromethorphan in the human being is increased about 15- to about 25-fold as compared to administration of 60 mg of dextromethorphan hydrobromide without bupropion or as compared to administration of a single dose of the combination of bupropion and dextromethorphan.

(28) In some embodiments, after eight days of receiving the combination of bupropion and dextromethorphan twice a day, the C.sub.min of dextromethorphan in the human being is increased about 35- to about 45-fold as compared to administration of 60 mg of dextromethorphan hydrobromide without bupropion or as compared to administration of a single dose of the combination of bupropion and dextromethorphan.

(29) In some embodiments, after eight days of receiving the combination of bupropion and dextromethorphan twice a day, the AUC.sub.0-12 of dextromethorphan in the human being is

increased about 25- to about 45-fold as compared to administration of 60 mg of dextromethorphan hydrobromide without bupropion or as compared to administration of a single dose of the combination of bupropion and dextromethorphan.

(30) In some embodiments, after eight days of receiving the combination of bupropion and dextromethorphan twice a day, the C.sub.max of dextromethorphan in the human being is about 75-80 ng/ml.

(31) In some embodiments, after eight days of receiving the combination of bupropion and dextromethorphan twice a day, the C.sub.min of dextromethorphan is about 42-50 ng/mL.

(32) In some embodiments, after eight days of receiving the combination of bupropion and dextromethorphan twice a day, the AUC.sub.0-12 of dextromethorphan in the human being is about 755 ng.Math.hr/mL.

(33) In some embodiments, after eight days of receiving the combination of bupropion and dextromethorphan twice a day, the C.sub.max of bupropion in the human being is about 85-90 ng/ml.

(34) In some embodiments, after eight days of receiving the combination of bupropion and dextromethorphan twice a day, the C.sub.min of bupropion is about 25-35 ng/ml.

(35) In some embodiments, after eight days of receiving the combination of bupropion and dextromethorphan twice a day, the AUC.sub.0-12 of bupropion in the human being is about 660-670 ng.Math.hr/mL.

Example 1

(36) An open label Phase III clinical trial was conducted using a tablet containing 45 mg dextromethorphan hydrobromide and 105 mg of bupropion hydrochloride with modulated delivery. This tablet was administered twice a day to patients suffering from major depressive disorder. A total of 611 patients participated in the trial, and a total of 597 patients were treated for at least 6 months when the trial was concluded. The mean MADRS score of the total patient population was 32.7 prior to treatment. The results for the total patient population are summarized in Table 1.

(37) TABLE-US-00001 TABLE 1 MADRS reduction for all patients after treatment Timepoint MADRS Reduction-all patients Baseline 0 1 week -10.4 2 weeks -14.7 6 weeks -20.6

(38) A total of 37 of these patients suffered from major depressive disorder with suicidal ideation, defined as a score of ≥ 3 on the Suicidality Item of the Montgomery-Åsberg Depression Rating Scale (MADRS-SI). For the patients with suicidal ideation, the mean MADRS score was 36.8 and the mean MADRS-SI score was 3.4 prior to treatment. The results for these patients are summarized in Table 2.

(39) TABLE-US-00002 TABLE 2 MADRS reduction for suicidal ideation patients after treatment Timepoint MADRS Reduction-suicidal ideation patients Baseline 0 1 week -12.9 2 weeks -17.8 6 weeks -22.8

(40) Additionally, in the patients who suffered from suicidal ideation, the MADRS-SI score was reduced by 67.1% at the end of 1 week of treatment, 73.5% at the end of 2 weeks of treatment, and 82.4% at the end of 4 weeks of treatment as compared with baseline. This is potentially lifesaving because it shows a quick reduction in the risk of suicide.

Claims

1. A method of treating depression and reducing risk of suicide, comprising selecting a human being suffering from major depressive disorder and having a score of 3 or greater on the Suicidality Item of the Montgomery-Åsberg Depression Rating Scale (MADRS-SI) and a score of at least 35 on the Montgomery-Åsberg Depression Rating Scale (MADRS), and administering a combination of about 90 mg to about 120 mg of bupropion hydrochloride, or a molar equivalent amount of another form of bupropion, and about 40 mg to about 50 mg of dextromethorphan hydrobromide, or a molar equivalent amount of another form of dextromethorphan, to a human being; wherein the

- combination is administered twice a day to the human being.
2. The method of claim 1, wherein the combination comprises about 105 mg of bupropion hydrochloride, or a molar equivalent amount of another form of bupropion, and about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of another form of dextromethorphan.
 3. The method of claim 1, wherein the combination is administered twice a day for at least one week.
 4. The method of claim 1, wherein the combination is administered twice a day for at least two weeks.
 5. The method of claim 1, wherein the combination is administered twice a day for at least six weeks.
 6. The method of claim 1, wherein the MADRS-SI of the human being is reduced by at least 30% after the combination is administered to the human being twice a day for one week.
 7. The method of claim 1, wherein the MADRS-SI of the human being is reduced by at least 50% after the combination is administered to the human being twice a day for two weeks.
 8. The method of claim 1, wherein the MADRS-SI of the human being is reduced by at least 60% after the combination is administered to the human being twice a day for four weeks.
 9. The method of claim 1, wherein after eight days of administration of the combination twice a day, the C.sub.max of dextromethorphan in the human being is increased about 15-to about 25-fold as compared to administration of a single dose of the combination.
 10. The method of claim 1, wherein after eight days of administering the combination twice a day, the C.sub.min of dextromethorphan in the human being is increased about 35-to about 45-fold as compared to administering a single dose of the combination.
 11. The method of claim 1, wherein after eight days of administering the combination twice a day, the AUC.sub.0-12 of dextromethorphan in the human being is increased about 25-to about 45-fold as compared to administering a single dose of the combination.
 12. The method of claim 2, wherein after eight days of administering the combination twice a day, the C.sub.max of dextromethorphan in the human being is about 75 ng/ml to about 80 ng/ml.
 13. The method of claim 2, wherein after eight days of administering the combination twice a day, the C.sub.min of dextromethorphan is about 42 ng/ml to about 50 ng/mL.
 14. The method of claim 2, wherein after eight days of administering the combination twice a day, the AUC.sub.0-12 of dextromethorphan in the human being is about 755 ng.Math.hr/mL.
 15. The method of claim 2, wherein after eight days of administering the combination twice a day, the C.sub.max of bupropion in the human being is about 85 ng/ml to about 90 ng/ml.
 16. The method of claim 2, wherein after eight days of administering the combination twice a day, the C.sub.min of bupropion is about 25 ng/ml to about 35 ng/ml.
 17. The method of claim 2, wherein after eight days of administering the combination twice a day, the AUC.sub.0-12 of bupropion in the human being is about 660 ng.Math.hr/mL to about 670 ng.Math.hr/mL.
-